Klinické štúdie nutraceutík

Je zrejmé, že výživové doplnky v kombinácii s adekvátnymi úpravami stravovania a životného štýlu upravujú hladiny lipidov. ArmoLIPID PLUS® sú príklady takýchto výživových doplnkov alebo nutraceutík.1

Viac informácií o produkte ArmoLIPID PLUS® nájdete tu.

Klinické štúdie týkajúce sa nutraceutík

Klinické štúdie týkajúce sa nutraceutík

  1. Banach M, Patti AM, Giglio RV, et al. The Role of Nutraceuticals in Statin Intolerant Patients. J Am Coll Cardiol. 2018;72(1):96-118. https://www.ncbi.nlm.nih.gov/pubmed/29957236.2
  2. Guardamagna O, Abello F, Baracco V, et al. The treatment of hypercholesterolemic children: efficacy and safety of a combination of red yeast rice extract and policosanols. Nutr Metab Cardiovasc Dis. 2011;21(6):424-9. K dispozícii na stránke: https://www.ncbi.nlm.nih.gov/pubmed/20153154. Prístup 2. decembra 2019.3
  3. Guardamagna et al.Nutr Metab Cardiovasc Dis. 2011; 21;424-429
  4. Sanidas et al.Hellenic J Cardiol. 2018. pii: S1109-9666(18)30245-8

Klinické štúdie týkajúce sa produktu ArmoLIPID plus®

  1. Barrios V, Escobar C, Cicero AF, et al. A nutraceutical approach (Armolipid Plus) to reduce total and LDL cholesterol in individuals with mild to moderate dyslipidemia: Review of the clinical evidence. Atheroscler Suppl. 2017;24:1–15. https://www.ncbi.nlm.nih.gov/pubmed/279987144
  2. Cicero AFG, Fogacci F, Bove M, et al. Optimizing Lipid Pattern by Adding a Combined Nutraceutical or Pravastatin to Fenofibrate Treatment in Hypertriglyceridemic Subjects: Single Site, Randomized, Open-Label, Post-Market Clinical Investigation. High Blood Press Cardiovasc Prev. 2018;25(4):355-359. https://www.ncbi.nlm.nih.gov/pubmed/302294625
  3. D'Addato S, Scandiani L, Mombelli G, et al. Effect of a food supplement containing berberine, monacolin K, hydroxytyrosol and coenzyme Q10 on lipid levels: a randomized, double-blind, placebo controlled study. Drug Des Devel Ther. 2017;11:1585–1592. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5447697/6
  4. De Castro-Orós I, Solà R, Valls RM, et al. Genetic Variants of LDLR and PCSK9 Associated with Variations in Response to Antihypercholesterolemic Effects of Armolipid Plus with Berberine. PLoS One. 2016;11(3):e0150785. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4807809/7
  5. Galletti F, Fazio V, Gentile M, et al. Efficacy of a nutraceutical combination on lipid metabolism in patients with metabolic syndrome: a multicenter, double blind, randomized, placebo controlled trial. Lipids Health Dis. 2019;18(1):66. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6421674/8
  6. Gentile M, Calcaterra I, Strazzullo A, et al. Effects of Armolipid Plus on small dense LDL particles in a sample of patients affected by familial combined hyperlipidemia. Clin Lipidol. 2015;10(6):475–480. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4821502/9
  7. Marazzi G, Campolongo G, Pelliccia F, et al. Comparison of Low-Dose Statin Versus Low-Dose Statin + Armolipid Plus in High-Intensity Statin-Intolerant Patients With a Previous Coronary Event and Percutaneous Coronary Intervention (ADHERENCE Trial). Am J Cardiol. 2017;120(6):893-897. https://www.ncbi.nlm.nih.gov/pubmed/2878102610
  8. Marazzi G, Campolongo G, Pelliccia F, et al. Usefulness of Low-Dose Statin Plus Ezetimibe and/or Nutraceuticals in Patients With Coronary Artery Disease Intolerant to High-Dose Statin Treatment. Am J Cardiol. 2019;123(2):233-238. https://www.ncbi.nlm.nih.gov/pubmed/3042018411
  9. Marazzi G, Pelliccia F, Campolongo G, et al. Usefulness of Nutraceuticals (Armolipid Plus) Versus Ezetimibe and Combination in Statin-Intolerant Patients With Dyslipidemia With Coronary Heart Disease. Am J Cardiol. 2015;116(12):1798-801. https://www.ncbi.nlm.nih.gov/pubmed/2661112012
  10. Mercurio V, Pucci G, Bosso G, et al. A nutraceutical combination reduces left ventricular mass in subjects with metabolic syndrome e and left ventricular hypertrophy: A multicenter, randomized, double-blind, placebo-controlled trial. Clin Nutr. 2019; pii: S0261-5614(19)30283-3. https://www.ncbi.nlm.nih.gov/pubmed/3137111413
  11. Millán J, Cicero AF, Torres F, et al. Effects of a nutraceutical combination containing berberine (BRB), policosanol, and red yeast rice (RYR), on lipid profile in hypercholesterolemic patients: A meta-analysis of randomised controlled trials. Clin Investig Arterioscler. 2016;28(4):178-87. https://www.ncbi.nlm.nih.gov/pubmed/2713139514
  12. Ruscica M, Gomaraschi M, Mombelli G, et al. Nutraceutical approach to moderate cardiometabolic risk: results of a randomized, double-blind and crossover study with Armolipid Plus. J Clin Lipidol. 2014;8(1):61-8. https://www.ncbi.nlm.nih.gov/pubmed/2452868615
  13. Solà R, Valls RM, Puzo J, et al. Effects of poly-bioactive compounds on lipid profile and body weight in a moderately hypercholesterolemic population with low cardiovascular disease risk: a multicenter randomized trial. PLoS One. 2014;9(8):e101978. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4118855/16
  14. Trimarco V, Battistoni A, Tocci G, et al. Single blind, multicentre, randomized, controlled trial testing the effects of a novel nutraceutical compound on plasma lipid and cardiovascular risk factors: Results of the interim analysis. Nutr Metab Cardiovasc Dis. 2017;27(10):850-857. https://www.ncbi.nlm.nih.gov/pubmed/2896579717
  15. Ward NC, Pang J, Ryan JDM, et al. Nutraceuticals in the management of patients with statin-associated muscle symptoms, with a note on real-world experience. Clin Cardiol. 2018;41(1):159–165. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6489823/18
  16. Guardamagna O, Abello F, Baracco V, et al. The treatment of hypercholesterolemic children: efficacy and safety of a combination of red yeast rice extract and policosanols. Nutr Metab Cardiovasc Dis. 2011;21(6):424-9. https://www.ncbi.nlm.nih.gov/pubmed/2015315419
  17. Affuso et al.Neutraceuticals in veteniary medicine.Nutr Metab Cardiovasc Dis.2010 20(9):656-661.
  18. Gonnelli S, Caffarelli C, Stolakis K, et al. Efficacy and Tolerability of a Nutraceutical Combination (Red Yeast Rice, Policosanols, and Berberine) in Patients with Low-Moderate Risk Hypercholesterolemia: A Double-Blind, Placebo-Controlled Study. Curr Ther Res Clin Exp. 2014;77:1–6.
  19. Pirro M, Francisci D, Bianconi V. NUtraceutical TReatment for hYpercholesterolemia in HIV-infected patients: The NU-TRY(HIV) randomized cross-over trial. 2019;280:51-57.
  20. Manfrin A, Trimarco V, Manzi MV, et al. A single blind, multicenter, randomized controlled trial to evaluate the effectiveness and cost of a novel nutraceutical (LopiGLIK®) lowering cardiovascular disease risk. Clinicoecon Outcomes Res. 2018;10:601–609. Giampietro et al. Clinical efficacy of a nutraceutical approach for the management of dyslipidemia in metabolic disorders: A one-year treatment with armolipid plus. Journal of Cardiol Ther; 20185(1): 701-706.
  21. Affuso F, Mercurio V, Ruvolo A, et al. A nutraceutical combination improves insulin sensitivity in patients with metabolic syndrome. World J Cardio 2012;4(3):77–83.
  22. Pissicotta L.Bellochio A, Bertoloni S. Nutraceutical pill containing berberine versus ezetimibe on plasma lipid pattern in hypercholesterolemic subjects and its additive effect in patients with familial hypercholesterolemia on stable cholesterol-lowering treatment.Lip in Health and Dis. 2015;11:123.
  23. Manfrin A, Trimarco V, Manzi MV,et al. A single blind, multicenter, randomized controlled trial to evaluate the effectiveness and cost of a novel nutraceutical (LopiGLIK®) lowering cardiovascular disease risk. Clinicoecon Outcomes Res. 2018;10:601–609.
  24. Zanardi et al. Minerva Ginecol 64;2012:431-435
  25. Pirro et al. Clinical efficacy of a nutraceutical approach for the management of dyslipidemia in metabolic disorders: A one-year treatment with Armolipid Plus.
  26. Ward et al. Nutraceuticals in the management of patients with statin‐associated muscle symptoms, with a note on real‐world experience.Clinical Cardiology. 2018;41:159–165

ArmoLIPID PLUS®

ArmoLIPID PLUS® je doplnok výživy, ktorý môže pomôcť kontrolovať hladinu cholesterolu okrem zdravej stravy a cvičenia.

Čítaj viac

Preventívne stratégie a liečba

Pri kontrole hladín cholesterolu môžu pomôcť rôzne intervencie, od úpravy životného štýlu až po farmakologickú liečbu.

Čítaj viac

Posúdené lekárom zo spoločnosti Viatris 01 December 2020

  • Zdroje

    1. Mach F, Baigent C, Catapano AL, et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk: The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS), Eur Heart J. 2019; pii: ehz455.
    2. Banach M, Patti AM, Giglio RV, et al. The Role of Nutraceuticals in Statin Intolerant Patients. J Am Coll Cardiol. 2018;72(1):96-118.
    3. Guardamagna O, Abello F, Baracco V, et al. The treatment of hypercholesterolemic children: efficacy and safety of a combination of red yeast rice extract and policosanols. Nutr Metab Cardiovasc Dis. 2011;21(6):424-9. Available at:  https://www.ncbi.nlm.nih.gov/pubmed/20153154. Accessed on 02 December 2019.
    4. Barrios V, Escobar C, Cicero AF, et al. A nutraceutical approach (Armolipid Plus) to reduce total and LDL cholesterol in individuals with mild to moderate dyslipidemia: Review of the clinical evidence. Atheroscler Suppl. 2017;24:1–15.
    5. Cicero AFG, Fogacci F, Bove M, et al. Optimizing Lipid Pattern by Adding a Combined Nutraceutical or Pravastatin to Fenofibrate Treatment in Hypertriglyceridemic Subjects: Single Site, Randomized, Open-Label, Post-Market Clinical Investigation. High Blood Press Cardiovasc Prev. 2018;25(4):355-359.
    6. D'Addato S, Scandiani L, Mombelli G, et al. Effect of a food supplement containing berberine, monacolin K, hydroxytyrosol and coenzyme Q10 on lipid levels: a randomized, double-blind, placebo controlled study. Drug Des Devel Ther. 2017;11:1585–1592.
    7. De Castro-Orós I, Solà R, Valls RM, et al. Genetic Variants of LDLR and PCSK9 Associated with Variations in Response to Antihypercholesterolemic Effects of Armolipid Plus with Berberine. PLoS One. 2016;11(3):e0150785.
    8. Galletti F, Fazio V, Gentile M, et al. Efficacy of a nutraceutical combination on lipid metabolism in patients with metabolic syndrome: a multicenter, double blind, randomized, placebo controlled trial. Lipids Health Dis. 2019;18(1):66.
    9. Gentile M, Calcaterra I, Strazzullo A, et al. Effects of Armolipid Plus on small dense LDL particles in a sample of patients affected by familial combined hyperlipidemia. Clin Lipidol. 2015;10(6):475–480.
    10. Marazzi G, Campolongo G, Pelliccia F, et al. Comparison of Low-Dose Statin Versus Low-Dose Statin + Armolipid Plus in High-Intensity Statin-Intolerant Patients With a Previous Coronary Event and Percutaneous Coronary Intervention (ADHERENCE Trial). Am J Cardiol. 2017;120(6):893-897.
    11. Marazzi G, Campolongo G, Pelliccia F, et al. Usefulness of Low-Dose Statin Plus Ezetimibe and/or Nutraceuticals in Patients With Coronary Artery Disease Intolerant to High-Dose Statin Treatment. Am J Cardiol. 2019;123(2):233-238.
    12. Marazzi G, Pelliccia F, Campolongo G, et al. Usefulness of Nutraceuticals (Armolipid Plus) Versus Ezetimibe and Combination in Statin-Intolerant Patients With Dyslipidemia With Coronary Heart Disease. Am J Cardiol. 2015;116(12):1798-801.
    13. Mercurio V, Pucci G, Bosso G, et al. A nutraceutical combination reduces left ventricular mass in subjects with metabolic syndrome e and left ventricular hypertrophy: A multicenter, randomized, double-blind, placebo-controlled trial. Clin Nutr. 2019; pii: S0261-5614(19)30283-3.
    14. Millán J, Cicero AF, Torres F, et al. Effects of a nutraceutical combination containing berberine (BRB), policosanol, and red yeast rice (RYR), on lipid profile in hypercholesterolemic patients: A meta-analysis of randomised controlled trials. Clin Investig Arterioscler. 2016;28(4):178-87.
    15. Ruscica M, Gomaraschi M, Mombelli G, et al. Nutraceutical approach to moderate cardiometabolic risk: results of a randomized, double-blind and crossover study with Armolipid Plus. J Clin Lipidol. 2014;8(1):61-8.
    16. Solà R, Valls RM, Puzo J, et al. Effects of poly-bioactive compounds on lipid profile and body weight in a moderately hypercholesterolemic population with low cardiovascular disease risk: a multicenter randomized trial. PLoS One. 2014;9(8):e101978.
    17. Trimarco V, Battistoni A, Tocci G, et al. Single blind, multicentre, randomized, controlled trial testing the effects of a novel nutraceutical compound on plasma lipid and cardiovascular risk factors: Results of the interim analysis. Nutr Metab Cardiovasc Dis. 2017;27(10):850-857.
    18. Ward NC, Pang J, Ryan JDM, et al. Nutraceuticals in the management of patients with statin-associated muscle symptoms, with a note on real-world experience. Clin Cardiol. 2018;41(1):159–165.
    19. Guardamagna O, Abello F, Baracco V, et al. The treatment of hypercholesterolemic children: efficacy and safety of a combination of red yeast rice extract and policosanols. Nutr Metab Cardiovasc Dis. 2011;21(6):424-9.